130,873 Shares in Edwards Lifesciences Corporation $EW Acquired by Strs Ohio

Key Points

• Strs Ohio has made a new investment of approximately $9.49 million in Edwards Lifesciences Corporation, acquiring 130,873 shares during the first quarter.
• Edwards Lifesciences reported $1.53 billion in revenue for the most recent quarter, exceeding analyst expectations by $40 million, with earnings per share beating estimates by 5 cents.
• Several analysts have raised their price targets for Edwards Lifesciences, with Royal Bank of Canada increasing it from $85.00 to $89.00 and other firms maintaining a dominant "buy" rating.

Strs Ohio bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 130,873 shares of the medical research company's stock, valued at approximately $9,486,000.

Other hedge funds also recently bought and sold shares of the company. Arlington Trust Co LLC grew its holdings in Edwards Lifesciences by 1.2% during the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock worth $804,000 after acquiring an additional 135 shares during the period. Valeo Financial Advisors LLC grew its holdings in Edwards Lifesciences by 2.8% during the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock worth $372,000 after acquiring an additional 142 shares during the period. Versant Capital Management Inc grew its holdings in Edwards Lifesciences by 9.3% during the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock worth $123,000 after acquiring an additional 145 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after acquiring an additional 145 shares during the period. Finally, Kera Capital Partners Inc. boosted its position in Edwards Lifesciences by 5.0% during the first quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company's stock worth $224,000 after purchasing an additional 148 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

EW traded down $0.64 on Thursday, hitting $74.56. 8,315,855 shares of the company traded hands, compared to its average volume of 3,759,610. The company has a 50 day moving average of $78.76 and a 200-day moving average of $75.49. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $43.77 billion, a PE ratio of 10.73, a PEG ratio of 3.63 and a beta of 1.07. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

EW has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft increased their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Evercore ISI increased their price target on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a research report on Friday, July 25th. BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a research report on Tuesday, July 29th. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Finally, The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $87.17.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.